Gilead Sciences is rated a Strong Buy due to strong Q4 2024 results and a robust HIV franchise. Check out my 12-month price ...

Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments.

Gilead Sciences Inc (GILD) reports robust sales growth, driven by HIV and oncology advancements, despite challenges from ...

Marking World Cancer Day 2025, this week's Executive Q&A is with Diego Santoro, General Manager & Head of International ...

Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) jumped 8.6% in the morning session after the company ...

With Gilead Sciences' long-acting lenacapavir unlocking a reinvigorated focus on the pre-exposure prophylaxis (PrEP) market ...

Gilead Sciences has battled back from a pipeline disappointment last year to its highest stock price in nearly a decade.

Gilead Sciences reported its fourth-quarter financial results after Tuesday's closing bell. Here's a look at the highlights ...

Cindy Perettie; Executive Vice President of Kite; Gilead Sciences Inc. Geoffrey Meacham; Analyst; Citi. Terence Flynn; Analyst; Morgan Stanley. Timothy Anderson; Analyst; BofA Glo ...

Gilead Sciences faces revenue growth challenges as its blockbuster drugs lose exclusivity by 2033. Check out my ...

Gilead Sciences posted fourth-quarter results that exceeded Wall Street estimates on Tuesday as its HIV drug sales rose 16% ...